headshot

Karen A. Blindauer, MD

Chief, Professor

Locations

  • Froedtert Hospital
  • Neuroscience Institute – Specialty Clinics

Specialties

  • Neurology

Languages

  • English

New & Established Patients Call

Education

  • MD - Doctor of Medicine

Biography

Appointments

Adult Division Chief Director, Movement Disorders Program

Specialty

Adult Neurology

Subspecialties

Parkinson's Disease
Essential Tremor
Movement Disorders
Botulinum Toxin Injection for Dystonia
Deep Brain Stimulation (DBS)

Training

Internal Medicine Internship, Medical College of Wisconsin, Milwaukee, WI, 1993 - 1994

Neurology Residency, Medical College of Wisconsin, Milwaukee, WI, 1994 - 1997

Movement Disorders and Experimental Therapeutics Fellowship, University of Rochester, Rochester, NY, 1997 - 1999

Societies

American Academy of Neurology
American Medical Association
Movement Disorders Society

View Faculty Collaboration Database profile

Honors and Awards

Delta Sigma Nu Scholastic Honor Society, 1988
Scott Foundation Scholarship, 1989
Cornelius G. Dyke Award for Excellence in Neurology, 1993
David Fine MD Award for Excellence in Post Graduate Training, 1997
Alpha Omega Alpha Medical Honor Society, 1993
Dystonia Medical Research Foundation, Dystonia Doctor of Excellence Award, 2000
Selected for inclusion in Best Doctors of America

Research Interests

Parkinson's Disease, Dystonia, Essential Tremor, Huntington's Disease

Publications

  • Consensus-Based Attributes for Identifying Patients With Spasmodic Dysphonia and Other Voice Disorders.

    (Ludlow CL, Domangue R, Sharma D, Jinnah HA, Perlmutter JS, Berke G, Sapienza C, Smith ME, Blumin JH, Kalata CE, Blindauer K, Johns M, Hapner E, Harmon A, Paniello R, Adler CH, Crujido L, Lott DG, Bansberg SF, Barone N, Drulia T, Stebbins G.) JAMA Otolaryngol Head Neck Surg. 2018 08 01;144(8):657-665 PMID: 29931028 PMCID: PMC6143004 SCOPUS ID: 2-s2.0-85051953234 06/23/2018

  • Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial.

    (Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, Evans S, Beck C, Orme C, Edicola J, Christopher E.) JAMA. 2016 Jul 05;316(1):40-50 PMID: 27380342 SCOPUS ID: 2-s2.0-84977592334 07/06/2016

  • Clinical-Genetic Associations in the Prospective Huntington at Risk Observational Study (PHAROS): Implications for Clinical Trials.

    (Huntington Study Group PHAROS Investigators, Biglan KM, Shoulson I, Kieburtz K, Oakes D, Kayson E, Shinaman MA, Zhao H, Romer M, Young A, Hersch S, Penney J, Marder K, Paulsen J, Quaid K, Siemers E, Tanner C, Mallonee W, Suter G, Dubinsky R, Gray C, Nance M, Bundlie S, Radtke D, Kostyk S, Baic C, Caress J, Walker F, Hunt V, O'Neill C, Chouinard S, Factor S, Greenamyre T, Wood-Siverio C, Corey-Bloom J, Song D, Peavy G, Moskowitz C, Wesson M, Samii A, Bird T, Lipe H, Blindauer K, Marshall F, Zimmerman C, Goldstein J, Rosas D, Novak P, Caviness J, Adler C, Duffy A, Wheelock V, Tempkin T, Richman D, Seeberger L, Albin R, Chou KL, Racette B, Perlmutter JS, Perlman S, Bordelon Y, Martin W, Wieler M, Leavitt B, Raymond L, Decolongon J, Clarke L, Jankovic J, Hunter C, Hauser RA, Sanchez-Ramos J, Furtado S, Suchowersky O, Klimek ML, Guttman M, Sethna R, Feigin A, Cox M, Shannon B, Percy A, Dure L, Harrison M, Johnson W, Higgins D, Molho E, Nickerson C, Evans S, Hobson D, Singer C, Galvez-Jimenez N, Shannon K, Comella C, Ross C, Saint-Hilaire MH, Testa C, Rosenblatt A, Hogarth P, Weiner W, Como P, Kumar R, Cotto C, Stout J, Brocht A, Watts A, Eberly S, Weaver C, Foroud T, Gusella J, MacDonald M, Myers R, Fahn S, Shults C.) JAMA Neurol. 2016 Jan;73(1):102-10 PMID: 26569098 SCOPUS ID: 2-s2.0-84954207601 11/17/2015

  • Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease.

    (Nalls MA, Pankratz N, Lill CM, Do CB, Hernandez DG, Saad M, DeStefano AL, Kara E, Bras J, Sharma M, Schulte C, Keller MF, Arepalli S, Letson C, Edsall C, Stefansson H, Liu X, Pliner H, Lee JH, Cheng R, International Parkinson's Disease Genomics Consortium (IPDGC), Parkinson's Study Group (PSG) Parkinson's Research: The Organized GENetics Initiative (PROGENI), 23andMe, GenePD, NeuroGenetics Research Consortium (NGRC), Hussman Institute of Human Genomics (HIHG), Ashkenazi Jewish Dataset Investigator, Cohorts for Health and Aging Research in Genetic Epidemiology (CHARGE), North American Brain Expression Consortium (NABEC), United Kingdom Brain Expression Consortium (UKBEC), Greek Parkinson's Disease Consortium, Alzheimer Genetic Analysis Group, Ikram MA, Ioannidis JP, Hadjigeorgiou GM, Bis JC, Martinez M, Perlmutter JS, Goate A, Marder K, Fiske B, Sutherland M, Xiromerisiou G, Myers RH, Clark LN, Stefansson K, Hardy JA, Heutink P, Chen H, Wood NW, Houlden H, Payami H, Brice A, Scott WK, Gasser T, Bertram L, Eriksson N, Foroud T, Singleton AB.) Nat Genet. 2014 Sep;46(9):989-93 PMID: 25064009 PMCID: PMC4146673 SCOPUS ID: 2-s2.0-84939599004 07/30/2014

  • A randomized clinical trial of high-dosage coenzyme Q10 in early Parkinson disease: no evidence of benefit.

    (Parkinson Study Group QE3 Investigators, Beal MF, Oakes D, Shoulson I, Henchcliffe C, Galpern WR, Haas R, Juncos JL, Nutt JG, Voss TS, Ravina B, Shults CM, Helles K, Snively V, Lew MF, Griebner B, Watts A, Gao S, Pourcher E, Bond L, Kompoliti K, Agarwal P, Sia C, Jog M, Cole L, Sultana M, Kurlan R, Richard I, Deeley C, Waters CH, Figueroa A, Arkun A, Brodsky M, Ondo WG, Hunter CB, Jimenez-Shahed J, Palao A, Miyasaki JM, So J, Tetrud J, Reys L, Smith K, Singer C, Blenke A, Russell DS, Cotto C, Friedman JH, Lannon M, Zhang L, Drasby E, Kumar R, Subramanian T, Ford DS, Grimes DA, Cote D, Conway J, Siderowf AD, Evatt ML, Sommerfeld B, Lieberman AN, Okun MS, Rodriguez RL, Merritt S, Swartz CL, Martin WR, King P, Stover N, Guthrie S, Watts RL, Ahmed A, Fernandez HH, Winters A, Mari Z, Dawson TM, Dunlop B, Feigin AS, Shannon B, Nirenberg MJ, Ogg M, Ellias SA, Thomas CA, Frei K, Bodis-Wollner I, Glazman S, Mayer T, Hauser RA, Pahwa R, Langhammer A, Ranawaya R, Derwent L, Sethi KD, Farrow B, Prakash R, Litvan I, Robinson A, Sahay A, Gartner M, Hinson VK, Markind S, Pelikan M, Perlmutter JS, Hartlein J, Molho E, Evans S, Adler CH, Duffy A, Lind M, Elmer L, Davis K, Spears J, Wilson S, Leehey MA, Hermanowicz N, Niswonger S, Shill HA, Obradov S, Rajput A, Cowper M, Lessig S, Song D, Fontaine D, Zadikoff C, Williams K, Blindauer KA, Bergholte J, Propsom CS, Stacy MA, Field J, Mihaila D, Chilton M, Uc EY, Sieren J, Simon DK, Kraics L, Silver A, Boyd JT, Hamill RW, Ingvoldstad C, Young J, Thomas K, Kostyk SK, Wojcieszek J, Pfeiffer RF, Panisset M, Beland M, Reich SG, Cines M, Zappala N, Rivest J, Zweig R, Lumina LP, Hilliard CL, Grill S, Kellermann M, Tuite P, Rolandelli S, Kang UJ, Young J, Rao J, Cook MM, Severt L, Boyar K.) JAMA Neurol. 2014 May;71(5):543-52 PMID: 24664227 SCOPUS ID: 2-s2.0-84900479240 03/26/2014

  • Parkinson's disease disrupts both automatic and controlled processing of action verbs.

    (Fernandino L, Conant LL, Binder JR, Blindauer K, Hiner B, Spangler K, Desai RH.) Brain Lang. 2013 Oct;127(1):65-74 PMID: 22910144 PMCID: PMC3574625 SCOPUS ID: 2-s2.0-84880963780 08/23/2012

  • Where is the action? Action sentence processing in Parkinson's disease.

    (Fernandino L, Conant LL, Binder JR, Blindauer K, Hiner B, Spangler K, Desai RH.) Neuropsychologia. 2013 Jul;51(8):1510-7 PMID: 23624313 PMCID: PMC3731159 SCOPUS ID: 2-s2.0-84879151933 04/30/2013

  • Atypical parkinsonism and cerebellar ataxia

    (Blindauer K.) Movement Disorders: 100 Instructive Cases. 1 January 2008:61-63 SCOPUS ID: 2-s2.0-85056320369 01/01/2008

  • R1514Q substitution in Lrrk2 is not a pathogenic Parkinson's disease mutation

    (Nichols WC, Marek DK, Pauciulo MW, Pankratz N, Halter CA, Rudolph A, Shults CW, Wojcieszek J, Foroud T, Shults C, Marshall F, Oakes D, Rudolph A, Shinaman A, Marder K, Conneally PM, Foroud T, Halter C, Lyons K, Siemers E, Factor S, Higgins D, Evans S, Shill H, Stacy M, Danielson J, Marlor L, Williamson K, Jankovic J, Hunter C, Simon D, Ryan P, Scollins L, Saunders-Pullman R, Boyar K, Costan-Toth C, Ohmann E, Sudarsky L, Joubert C, Friedman J, Chou K, Fernandez H, Lannon M, Galvez-Jimenez N, Podichetty A, Lewitt P, DeAngelis M, O'Brien C, Seeberger L, Dingmann C, Judd D, Marder K, Fraser J, Harris J, Bertoni J, Peterson C, Chouinard S, Panisset M, Hall J, Poiffaut H, Calabrese V, Roberge P, Wojcieszek J, Belden J, Halter CA, Jennings D, Marek K, Mendick S, Reich S, Dunlop B, Jog M, Horn C, Rao J, Cook M, Uitti R, Turk M, Ajax T, Mannetter J, Panisset M, Hall J, Sethi K, Carpenter J, Ligon K, Narayan S, Woodward L, Blindauer K, Petit J, Elmer L, Aiken E, Davis K, Schell C, Wilson S, Velickovic M, Koller W, Phipps S, Feigin A, Gordon M, Hamann J, Licari E, Marotta-Kollarus M.) Movement Disorders. 15 January 2007;22(2):254-256 SCOPUS ID: 2-s2.0-33847700524 01/15/2007

  • Mutations in LRRK2 other than G2019S are rare in a north American-based sample of familial Parkinson's disease.

    (Pankratz N, Pauciulo MW, Elsaesser VE, Marek DK, Halter CA, Rudolph A, Shults CW, Foroud T, Nichols WC, Parkinson Study Group-PROGENI Investigators.) Mov Disord. 2006 Dec;21(12):2257-60 PMID: 17078063 SCOPUS ID: 2-s2.0-33846463019 11/02/2006

  • Rasagiline-associated motor improvement in PD occurs without worsening of cognitive and behavioral symptoms.

    (Elmer L, Schwid S, Eberly S, Goetz C, Fahn S, Kieburtz K, Oakes D, Blindauer K, Salzman P, Oren S, Prisco UL, Stern M, Shoulson I, Parkinson Study Group TEMPO, PRESTO Investigators.) J Neurol Sci. 2006 Oct 25;248(1-2):78-83 PMID: 16828804 SCOPUS ID: 2-s2.0-33750480538 07/11/2006

  • Effects of tyramine administration in Parkinson's disease patients treated with selective MAO-B inhibitor rasagiline.

    (deMarcaida JA, Schwid SR, White WB, Blindauer K, Fahn S, Kieburtz K, Stern M, Shoulson I, Parkinson Study Group TEMPO, PRESTO Tyramine Substudy Investigators and Coordinators.) Mov Disord. 2006 Oct;21(10):1716-21 PMID: 16856145 SCOPUS ID: 2-s2.0-33750296512 07/21/2006